Alkaline Monosodium L-Glutamate Formulation for Bioavailability

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current medicinal therapies for conditions like Gout, Arthritis, and other diseases are often complex and ineffective due to the misconceived belief that Monosodium L-Glutamate Monohydrate (MSLGM) causes adverse effects, despite its potential for medicinal use being underresearched.

Innovation Solution

A novel oral and topical composition of Monosodium L-Glutamate Monohydrate, adjusted to a pH of 7.5-9.0, combined with water and other ingredients like propylene glycol and polyacrylamide-based emulsions, to enhance bioavailability and stability, allowing for effective administration in fasting states to treat various conditions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If Monosodium L-Glutamate Monohydrate is used as a medicinal therapy, then treatment effectiveness is improved, but public perception of safety deteriorates due to the misconception that it causes adverse effects

Engineering Contradiction:
Improvetreatment effectivenessVSAvoidpublic perception of adverse effects
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful perception of MSG into a benefit by demonstrating its medicinal value. The formulation uses Monosodium L-Glutamate Monohydrate at controlled concentrations (5-10% w/w) to treat various conditions, transforming the substance previously feared as harmful into a therapeutic agent that triggers self-immunity and provides long-term relief

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent changes the parameters of MSG usage by controlling pH (7.5-9.0), concentration (5-10% w/w), and administration conditions (fasting state). These parameter changes optimize bioavailability and stability while addressing safety concerns through standardized formulation

Inventive Principle:
Principle #35Parameter changes

2Adaptability or versatility

If complex medicinal therapies are used for conditions like Gout and Arthritis, then treatment coverage is improved, but treatment simplicity deteriorates

Engineering Contradiction:
Improvetreatment coverageVSAvoidtreatment simplicity
Core Design Contradiction:
Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent creates a universal formulation that treats multiple conditions (Gout, Arthritis, Shingles, Acne, Herpes, Sarcoidosis, Cirrhosis, Prostate conditions, Cataracts, and COVID-19) with a single active ingredient - Monosodium L-Glutamate Monohydrate. This multi-functional approach simplifies treatment while maintaining broad adaptability across different diseases

Inventive Principle:
Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent segments the treatment approach by providing specific formulation variations for different administration routes (oral, topical, nasal, injection) and different conditions, allowing the core active ingredient to be delivered in optimized forms for each specific application

Inventive Principle:
Principle #1Segmentation

3Ease of manufacture

If Monosodium L-Glutamate Monohydrate is administered without pH adjustment, then formulation simplicity is improved, but bioavailability deteriorates

Engineering Contradiction:
Improveformulation simplicityVSAvoidbioavailability
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The patent changes the pH parameter to 7.5-9.0 to optimize the ionization state of Monosodium L-Glutamate Monohydrate, thereby improving its bioavailability and stability. This parameter adjustment ensures the compound remains in a form that is readily absorbed while maintaining formulation simplicity through the use of common pH adjustment agents like NaOH

Inventive Principle:
Principle #35Parameter changes

4Ease of operation

If Monosodium L-Glutamate Monohydrate is administered in non-fasting state, then administration convenience is improved, but absorption efficiency deteriorates

Engineering Contradiction:
Improveadministration convenienceVSAvoidabsorption efficiency
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The patent requires fasting state (two hours before or after food consumption) as a preliminary condition for administration. This preliminary action prevents food from interfering with the absorption of Monosodium L-Glutamate Monohydrate, ensuring optimal bioavailability while maintaining reasonable administration convenience through clear timing guidelines

Inventive Principle:
Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively treats conditions such as Gout, Arthritis, Shingles, and others by improving bioavailability and absorption, triggering self-immunity, and providing long-term relief or cure without adverse effects.

Implementation Method 1

triggering self immunity

Methodology Applied
Scientific EffectSelf-immunity triggering:

Data Source

PatentUS11147785B2Modified free amino acid formulation and uses
Publication Date: 2021.10.19 MENTKOW JACK

AI summary

A composition and methods of administration are provides utilizing Monosodium L-Glutamate Monohydrate in a stabilized form at an alkaline pH.